

| <b>FORM PTO-1449B</b><br><br><b>INFORMATION DISCLOSURE</b><br><b>CITATION</b> |                       | Attorney Docket:<br>4439-4032   | Serial No.: <b>10/533700</b><br>Not Yet Assigned |
|---|-----------------------|---|--|
|   |                       | Applicant:<br>Toshiyuki TAKAI et al.  |  |
|   |                       | Filing Date:<br>April 26, 2005  | Group Art Unit:<br>Not Yet Assigned              |
|   |                       | <b>NON PATENT LITERATURE DOCUMENTS</b>  |  |
| Examiner<br>Initials*   | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.             |  |
| AS  | 1.                    | YUASA T. et al., Deletion of fc gamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis, J. Exp. Med. (1999), Vol. 189, No. 1, p.187-94.   |  |
| AS  | 2.                    | TAKAI T. et al., Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice, Nature (1996), Vol. 379, No. 6563, p. 346-49.   |  |
| AS  | 3.                    | ODAKA M. et al., N-glycolylneuraminic acid-containing GM1 is a new molecule for serum antibody in Guillain-Barre syndrome, Ann. Neurol. (1998), Vol. 43, No. 6, p.829-34.   |  |
| Not considered  | 4.                    | KEIICHIRO SUSUKI et al., Jikusakugata Guillain-Barre Shokogun Model Dobutsu no Juritsu: 2 <sup>nd</sup> report, Men'ekisei Shinkei Shikkan ni Kansuru Chosa Kenkyuhan Heisei 12 Nendo Kenyu Hokokusho (2001), p.111-12. <span style="float: right;">No English Trans</span> |  |
|   | 5.                    |   |  |
|   | 6.                    |   |  |
|   | 7.                    |   |  |
|   | 8.                    |   |  |
|   | 9.                    |   |  |
|   | 10.                   |   |  |
|   | 11.                   |   |  |
|   | 12.                   |   |  |
|   | 13.                   |   |  |
|   | 14.                   |   |  |
|   | 15.                   |   |  |
|   | 16.                   |   |  |
|   | 17.                   |   |  |
|   | 18.                   |   |  |

|                       |               |                    |            |
|-----------------------|---------------|--------------------|------------|
| Examiner<br>Signature | /Anoop Singh/ | Date<br>Considered | 10/31/2006 |
|-----------------------|---------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.